4//SEC Filing
Sabag Mark 4
Accession 0000950170-24-027959
CIK 0000818686other
Filed
Mar 6, 7:00 PM ET
Accepted
Mar 7, 4:12 PM ET
Size
12.8 KB
Accession
0000950170-24-027959
Insider Transaction Report
Form 4
Sabag Mark
See "Remarks"
Transactions
- Exercise/Conversion
Ordinary Shares
2024-03-05+58,133→ 482,590 total - Exercise/Conversion
Ordinary Shares
2024-03-05+23,764→ 424,457 total - Exercise/Conversion
Restricted Share Units
2024-03-05−23,764→ 23,765 total→ Ordinary Shares (23,764 underlying) - Sale
Ordinary Shares
2024-03-05$13.52/sh−100,000$1,352,090→ 382,590 total - Exercise/Conversion
Restricted Share Units
2024-03-05−58,133→ 0 total→ Ordinary Shares (58,133 underlying)
Footnotes (5)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.41 to $13.61, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]Restricted share units were granted on March 5, 2021, with 23,764 vested on each of March 5, 2022, March 5, 2023 and March 5, 2024, and 23,765 vesting on March 5, 2025.
- [F5]Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024.
Documents
Issuer
TEVA PHARMACEUTICAL INDUSTRIES LTD
CIK 0000818686
Entity typeother
Related Parties
1- filerCIK 0001721442
Filing Metadata
- Form type
- 4
- Filed
- Mar 6, 7:00 PM ET
- Accepted
- Mar 7, 4:12 PM ET
- Size
- 12.8 KB